Clinical Trials on Vaccine for Meningococcal Disease

Total 30569 results

GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

Infections, Meningococcal

United States
CanSino Biologics Inc.

Recruiting

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Meningococcal Meningitis

Indonesia
St George's, University of London
Public Health England

Recruiting

Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study

HIV/AIDS | Meningococcal Disease

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

Meningitis | Meningococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines

Meningitis | Meningococcal Disease

Philippines
Michigan State University

Recruiting

Playing Games to Learn About Children's Vaccines Project

COVID-19 | Vaccine-Preventable Diseases | HPV

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland, Germany, Hungary, Spain
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Public Health England

Completed

Comparison of Two Meningococcal ACWY Conjugate Vaccines (PRIME)

Meningococcal Meningitis

United Kingdom
JN-International Medical Corporation

Completed

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines

Completed

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

Meningococcal Infections | Meningococcal Meningitis

Argentina, Chile, Czech Republic, Hungary, Italy
Armauer Hansen Research Institute, Ethiopia
World Health Organization; Addis Ababa University; LSHTM,UK

Completed

Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine (ETH-TVT)

Meningococcal Meningitis

Ethiopia
Pfizer

Completed

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (B1971042)

Meningitis, Meningococcal, Serogroup B

United States
Novartis Vaccines
GlaxoSmithKline

Completed

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Serogroup B Meningococcal Meningitis

Austria, Czechia, Finland, Germany, Italy
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

Healthy Volunteers | Meningococcal Immunisation

Argentina
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (MET55)

Healthy Volunteers (Meningococcal Infection)

India, South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (MET52)

Healthy Volunteers (Meningococcal Infection)

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33)

Healthy Volunteers (Meningococcal Infection)

Mexico, Russian Federation
Sanofi

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

Meningococcal Immunisation (Healthy Volunteers)

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon (MEQ00063)

Healthy Volunteers (Meningococcal Infection)

Lebanon, Turkey
GlaxoSmithKline

Completed

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

Infections, Meningococcal

United States, Australia, Finland, Estonia, Canada, Turkey, Czechia
GlaxoSmithKline

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Infections, Meningococcal

United States, Puerto Rico
GlaxoSmithKline

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Infections, Meningococcal

Mexico, Argentina
Epividian
AIDS Healthcare Foundation

Completed

COVID-19 Quantitative Antibody Titers & Booster Vaccinations

COVID-19 | COVID-19 Vaccines | Immunogenicity, Vaccine

United States
GlaxoSmithKline

Completed

Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants

Infections, Meningococcal
Insel Gruppe AG, University Hospital Bern

Recruiting

Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy (IMCAR)

Vaccine Immunity in CAR-T Cell Therapy Recipients

Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

Meningitis | Meningococcal Disease

United States
Novartis
Novartis Vaccines

Completed

Persistence of Immune Response After Vaccination With MCC

Prevention of Meningococcal Infection

United Kingdom
Novartis Vaccines

Completed

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

Prevention of Meningococcal Infection

Germany, Poland
The Immunobiological Technology Institute (Bio-Manguinhos)...

Unknown

Conjugate Vaccine Against Meningococcus C a Brazilian Project

Serogroup C Meningococcal Meningitis

Brazil
Children's Hospital Medical Center, Cincinnati

Completed

Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination

Health Care Utilization | Vaccine Preventable Disease

United States
London School of Hygiene and Tropical Medicine
Public Health England; Stanford University; World Health Organization; University... and other collaborators

Unknown

Maternal Immunization With MenAfriVac™

Meningitis | Meningococcal

Gambia
GlaxoSmithKline

Completed

Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers

Infections, Meningococcal
Public Health England

Withdrawn

Host-pathogen Interactions in Meningococcal Disease: Finding the Key That Fits the Lock (Lock and Key)

Meningitis

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children

Meningitis | Meningococcal Disease

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations

Meningitis | Meningococcal Infection

Canada
Novartis Vaccines
GlaxoSmithKline

Completed

Persistence of Antibody Response to N. Meningitidis Group C in Children

Prevention of Meningococcal Infection

Spain, Poland
Novartis Vaccines

Completed

Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

Prevention of Meningococcal Infection

United Kingdom
Novartis
Novartis Vaccines

Completed

Kinetics of B Cell Response in Infants Menjugate Vaccination

Prevention of Meningococcal Infection

United Kingdom
JN-International Medical Corporation

Completed

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Meningococcal Infections | Meningococcal Meningitis

United States
Pfizer

Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Infections, Meningococcal

Finland
IDeA States Pediatric Clinical Trials Network
National Institutes of Health (NIH); University of Nebraska; University of Montana

Completed

Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool (MoVeUP)

Telemedicine | Pediatric ALL | Vaccine Hesitancy | COVID-19 Vaccines

United States
Mayo Clinic

Completed

Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations (CERC)

Vaccine Preventable Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation

Meningitis | Meningococcal Infection

Russian Federation, India
Sanofi Pasteur, a Sanofi Company

Completed

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

Meningitis | Meningococcal Infection

United States

3

Subscribe